TICKERNOMICS Sign up
Last Update: 2023-10-04 11:35:26
Celsion Corp ( CLSN ) https://celsion.com
1.45USD
Sector:
Healthcare
Industry:
Biotechnology & Medical Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-12.91%
CLSN
SPY
36.71%
-86.46%
CLSN
SPY
70.96%
-96.45%
CLSN
SPY
262.36%
-99.88%
CLSN
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
13.19
-20.26
0.03
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.43
28.18
0.50
-177.39
0.00
0.87
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-6106.73
100.00
-5788.94
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.8606
-17878.77
-44.93
1.26
Other Earnings and Cash Flow Stats:
Celsion Corp ( CLSN ) Net Income TTM ($MM) is -28.26
Celsion Corp ( CLSN ) Operating Income TTM ($MM) is -23.68
Celsion Corp ( CLSN ) Owners' Earnings Annual ($MM) is -14.90
Celsion Corp ( CLSN ) Current Price to Owners' Earnings ratio is -0.89
Celsion Corp ( CLSN ) EBITDA TTM ($MM) is -22.97
Celsion Corp ( CLSN ) EBITDA Margin is -5788.94%
Capital Allocation:
Celsion Corp ( CLSN ) has paid 0.00 dividends per share and bought back -1.998264 million shares in the past 12 months
Celsion Corp ( CLSN ) has reduced its debt by 2.464443 million USD in the last 12 months
Capital Structure:
Celsion Corp ( CLSN ) Interest-bearing Debt ($MM) as of last quarter is 3
Celsion Corp ( CLSN ) Annual Working Capital Investments ($MM) are 2
Celsion Corp ( CLSN ) Book Value ($MM) as of last quarter is 26
Celsion Corp ( CLSN ) Debt/Capital as of last quarter is 14%
Other Balance Sheet Stats:
Celsion Corp ( CLSN ) has 10 million in cash on hand as of last quarter
Celsion Corp ( CLSN ) has 10 million of liabilities due within 12 months, and long term debt 5 as of last quarter
Celsion Corp ( CLSN ) has 9 common shares outstanding as of last quarter
Celsion Corp ( CLSN ) has 0 million USD of preferred stock value
Academic Scores:
Celsion Corp ( CLSN ) Altman Z-Score is -13.06 as of last quarter
Celsion Corp ( CLSN ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Celsion Corp ( CLSN ) largest shareholder is Vanguard Group Inc owning 152450 shares at 0.22 ($MM) value
Michael H Tardugno(an insider) Bought 4000 shares of Celsion Corp ( CLSN ) for the amount of $14120.00 on 2022-04-12
1.45% of Celsion Corp ( CLSN ) is held by insiders, and 15.56% is held by institutions
Celsion Corp ( CLSN ) went public on 1985-03-05
Other Celsion Corp ( CLSN ) financial metrics:
FCF:-22.44
Unlevered Free Cash Flow:-22.63
EPS:-3.01
Operating Margin:-6106.73
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-83.93
Beta:1.26
Buffet's Owners Earnings:-14.90
Price to Owner's Earnings:-0.89
About Celsion Corp ( CLSN ) :
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.